Document is current

Any future updates will be listed below

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

Crossref DOI link: https://doi.org/10.1007/s40120-023-00523-3

Published Online: 2023-07-17

Published Print: 2023-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark